Citation:Green SJ (2007) Gut Mucosa in HIV Infection: “Immune Milk” Solution. PLoS Med 4(2): e85. doi:10.1371/journal.pmed.0040085
Published: February 27, 2007
Copyright: © 2007 Shawn J. Green. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding:The author received no specific funding for this article.
Competing interests: This letter is not intended to promote, endorse, or support the use of any currently available commercial sources of colostrum or “immune milk.” Origo Bioscience Institute, a newly formed nonprofit, is interested in the development of low-tech, low-cost technology platforms for the production and processing of “immune milk” from cows and goats to prevent and treat diarrheal illness and associated malnutrition in developing nations.
In recent weeks, three noteworthy papers, published in PLoS Medicine, The Journal of Virology, and Nature Medicine, direct our attention to the gut as a critical target in HIV-1 infection and portal for therapeutic intervention.
In PLoS Medicine, Mehandru and colleagues report that over half of the CD4+ T cells in the gut mucosa are lost within the first few weeks after HIV-1 infection and remain consistently low, compared to peripheral blood sources, despite long term antiretroviral therapy; furthermore, of the few CD4+ T cells that persist in the gut, a significant increase in immune activation is observed . Consistent with earlier observation in SIV models, Veazey reminds us that the battle against HIV-1 should focus on the intestinal mucosa with therapeutic strategies to reduce gut immune activation .
The longitudinal study in The Journal of Virology by Guadalupe and colleagues showed a similar discordance in CD4+ T cells between restoration in peripheral blood and significant delay in the gut mucosa of chronic infected individuals during antiretroviral therapy. Here, the depletion in CD4+ T cells was associated with an increase in gut immune activation, CD8+ T cells, and associated inflammation with a corresponding decease in epithelial growth and repair-associated genes in gut mucosal tissue . Brenchley and colleagues suggest in Nature Medicine that HIV infection causes this breakdown in the gut mucosa resulting in a “leaky gut,” thus allowing translocation of gut-derived endotoxin and the subsequent triggering of immune activation .
Collectively, these observations suggest that an orally active therapeutic, used in conjunction with antiretroviral therapy, be designed to both block gut-derived microbial translocation and stimulate restitution of the gut epithelium. The hope would be to restore immunological integrity of the intestinal mucosal barrier, thereby controlling immune activation, both locally, in the gut mucosa, and systemically by suppressing cellular targets distal to the gut that may directly contribute to the progression of AIDS [5–8].
The design for such an orally active therapeutic may be found in the complex formula of bovine colostrum and “immune milk,” which has long been recognized to offer passive protection from a broad number of enteric bacterial and viral pathogens, primarily via the transfer of immunoglobulins and suppression of gut-associated inflammation with promotion of mucosal repair and regeneration.
The gut in chronic HIV-1-infected individuals appears to be reminiscent of newborn calves. Calves are born with a highly immature mucosal immune system and “leaky gut” which, if not immediately corrected, results in death due to infection and associated systemic immune activation. However, the cow's first milk rescues her calves from harmful gut microbes with a uniquely complex cocktail enriched with neutralizing polyclonal antibodies, cytokine tissue repair factors, and immune enhancing probiotics, such as Lactobacillus species.
Regular consumption of biologically active bovine colostrum has been known for years to promote the development of infantile gut-associated lymphoid tissue and enhance CD4+ levels, while suppressing CD8+ and inflammatory bowl disease (IBD), including ulcerative colitis and Crohn disease . The severity of IBD is often correlated with gut microbial-endotoxin translocation, which now appears in chronic HIV-1-infected individuals . Similar to bovine colostrum, “immune milk” from properly vaccinated cows affords passive immunity against bacterial, viral, and fungal infections in the human gastrointestinal tract, as well as taming gut inflammation .
Hence, there may be lessons learned from Bessie's “immune milk.” If viewed as a unique formula that has evolved to complement gut immunity, “immune milk” may also provide relief in chronic HIV-infected individuals. Initial studies have already shown that ingestion of colostrum alleviates refractory diarrhea in HIV patients with a corresponding increase in both body weight and peripheral blood CD4+ T cells [9,10]. As we learn more about the gut microenvironment in HIV-infected individuals, Bessie may prove to be a worthwhile platform for the consideration of “immune milk” exhibiting both microbial endotoxin and HIV-neutralizing activity along with its innate anti-inflammatory and tissue repair and regenerative properties.
- 1. Mehandru S,Poles MA,Tenner-Racz K,Jean-Pierre P,Manuelli V,et al. (2006) Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med 3: 484. doi:10.1371/journal.pmed.0030484.
- 2. Veazey RS,Lackner AA (2006) Impact of antiretroviral therapy on intestinal lymphoid tissues in HIV infection. PLoS Med 3: e515. doi:10.1371/journal.pmed.0030515.
- 3. Guadalupe M,Sankaran S,George MD,Reay E,Verhoeven D,et al. (2006) Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 80: 8236–8247.
- 4. Brenchley JM,Price DA,Schacker TW,Asher TE,Silvestri G,et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365–1371.
- 5. Playford RJ,MacDonald CE,Johnson WS (2000) Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders. Am J Clin Nutr 72: 514.
- 6. Korhonen H,Marnila P,Gill HS (2000) Bovine milk antibodies for health. Brit J Nutr 84: S135–S146.
- 7. Zeitlin L,Cone RA,Whaley KJ (1999) Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Emerg Infect Dis 5: 54–64.
- 8. Green SJ,Brendsel J (2006) Could the GI tract be a better portal for antibody therapy? Gut 55: 1681–1682.
- 9. Plettenberg A,Stoehr A,Stellbrink HJ,Albrecht H,Meigel W (1993) A preparation from bovine colostrum in the treatment of HIV-positive patients with chronic diarrhea. Clin Investig 71: 42–45.
- 10. Floren CH,Chinenye S,Elfstrand L,Hagman C,Ihse I (2006) ColoPlus, a new product based on bovine colostrum, alleviates HIV-associated diarrhoea. Scand J Gastroenterol 41: 682–686.